Great Valley Advisor Group Inc. Has $767,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Great Valley Advisor Group Inc. raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,239 shares of the medical research company’s stock after buying an additional 148 shares during the period. Great Valley Advisor Group Inc.’s holdings in IQVIA were worth $767,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Keyes Stange & Wooten Wealth Management LLC acquired a new stake in shares of IQVIA during the 3rd quarter valued at $200,000. Icon Wealth Advisors LLC raised its position in IQVIA by 1,608.1% in the third quarter. Icon Wealth Advisors LLC now owns 8,899 shares of the medical research company’s stock valued at $2,109,000 after purchasing an additional 8,378 shares during the last quarter. Raymond James Trust N.A. boosted its stake in shares of IQVIA by 2.9% during the third quarter. Raymond James Trust N.A. now owns 12,714 shares of the medical research company’s stock valued at $3,013,000 after purchasing an additional 353 shares in the last quarter. Eagle Asset Management Inc. grew its holdings in shares of IQVIA by 38.7% during the third quarter. Eagle Asset Management Inc. now owns 12,733 shares of the medical research company’s stock worth $2,791,000 after purchasing an additional 3,553 shares during the last quarter. Finally, Activest Wealth Management acquired a new position in shares of IQVIA in the third quarter valued at approximately $95,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $204.02 on Tuesday. The stock has a 50-day moving average of $221.96 and a 200-day moving average of $226.98. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market cap of $37.03 billion, a PE ratio of 26.77, a P/E/G ratio of 2.08 and a beta of 1.51.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Barclays decreased their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. The Goldman Sachs Group cut their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Truist Financial decreased their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Finally, Redburn Atlantic assumed coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.